Q-omics provides the consensus-scored LRRC37BP1 profile across patient tissues and cancer cell-line models. LRRC37BP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LRRC37BP1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, LRRC37BP1 RNA expression shows 20,878 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where LRRC37BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37BP1 survival associations across molecular data types. LRRC37BP1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37BP1 RNA expression–survival associations across cancer types. High LRRC37BP1 expression shows unfavorable associations in ACC, MESO, LIHC, KIRP, KICH and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LRRC37BP1 RNA expression.
This table summarizes LRRC37BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37BP1 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, LIHC, KIRP and BLCA. The KICH box plot shows higher LRRC37BP1 RNA expression in normal versus tumor tissue (log2 FC = −1.380, t-test p < 0.001).
This table shows molecular features associated with LRRC37BP1 in patient tissues and cancer cell lines. In patient samples, LRRC37BP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC37BP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
